Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 1
2005 1
2006 4
2007 2
2008 8
2009 2
2010 4
2011 5
2012 3
2013 2
2014 3
2017 4
2018 5
2019 1
2021 2
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Monitoring and assessing vaccine safety: a European perspective.
Lopalco PL, Johansen K, Ciancio B, De Carvalho Gomes H, Kramarz P, Giesecke J. Lopalco PL, et al. Among authors: johansen k. Expert Rev Vaccines. 2010 Apr;9(4):371-80. doi: 10.1586/erv.10.20. Expert Rev Vaccines. 2010. PMID: 20370548 Review.
Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
O Murchu E, Comber L, Jordan K, Hawkshaw S, Marshall L, O'Neill M, Ryan M, Teljeur C, Carnahan A, Pérez JJ, Robertson AH, Johansen K, Jonge J, Krause T, Nicolay N, Nohynek H, Pavlopoulou I, Pebody R, Penttinen P, Soler-Soneira M, Wichmann O, Harrington P. O Murchu E, et al. Among authors: johansen k. Rev Med Virol. 2023 May;33(3):e2329. doi: 10.1002/rmv.2329. Epub 2022 Feb 10. Rev Med Virol. 2023. PMID: 35142401
Systematic review of the efficacy, effectiveness and safety of cell-based seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
Jordan K, Murchu EO, Comber L, Hawkshaw S, Marshall L, O'Neill M, Teljeur C, Harrington P, Carnahan A, Pérez-Martín JJ, Robertson AH, Johansen K, Jonge J, Krause T, Nicolay N, Nohynek H, Pavlopoulou I, Pebody R, Penttinen P, Soler-Soneira M, Wichmann O, Ryan M. Jordan K, et al. Among authors: johansen k. Rev Med Virol. 2023 May;33(3):e2332. doi: 10.1002/rmv.2332. Epub 2022 Feb 8. Rev Med Virol. 2023. PMID: 35137512 Review.
Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
Comber L, O Murchu E, Jordan K, Hawkshaw S, Marshall L, O'Neill M, Teljeur C, Ryan M, Carnahan A, Pérez Martín JJ, Robertson AH, Johansen K, de Jonge J, Krause T, Nicolay N, Nohynek H, Pavlopoulou I, Pebody R, Penttinen P, Soler-Soneira M, Wichmann O, Harrington P. Comber L, et al. Among authors: johansen k. Rev Med Virol. 2023 May;33(3):e2330. doi: 10.1002/rmv.2330. Epub 2022 Feb 4. Rev Med Virol. 2023. PMID: 35119149 Review.
Systematic review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
O Murchu E, Comber L, Jordan K, Hawkshaw S, Marshall L, O'Neill M, Ryan M, Teljeur C, Carnahan A, Pérez JJ, Robertson AH, Johansen K, Jonge J, Krause T, Nicolay N, Nohynek H, Pavlopoulou I, Pebody R, Penttinen P, Soler-Soneira M, Wichmann O, Harrington P. O Murchu E, et al. Among authors: johansen k. Rev Med Virol. 2023 May;33(3):e2331. doi: 10.1002/rmv.2331. Epub 2022 Feb 2. Rev Med Virol. 2023. PMID: 35106885 Review.
46 results